Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CL Use To Be Limited To Emergencies – India Official

This article was originally published in PharmAsia News

Executive Summary

If India uses a compulsory licensing policy for pharmaceuticals, it is likely to confine the procedure to emergency needs only. Recent CL applications, such as one filed by Natco Pharma to export cancer generics of Roche's Tarceva (erlotinib hydrochloride) and Pfizer's Sutent (sunitinib malate) to Nepal, are unlikely to be granted. A senior official of the patent-overseeing Department of Industrial Policy and Promotion said the agency favors CL only in cases of "an extraordinary problem" such as a widespread epidemic that needs an immediate solution. (Click here for more

You may also be interested in...



How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell

Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.

Brexit: Life Science Firms In An ‘Impossible Position’

As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period. 

Novartis Advances Novel Kidney Disease Therapy Iptacopan

Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel